Humana Inc.

HUM Healthcare Healthcare Plans

Humana Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.7 billion, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 26.2%, EPS grew 27.9%, free cash flow grew 58.5% and total debt rose 13.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five; insiders bought in the last twelve months.

413.16 19.04 −4.41%
Market cap
$51.9B
P/E
38.8×
Fwd P/E
42.9×
Dividend yield
0.86%
F-score
6/9
Altman Z
4.66
Beneish M
−2.29
Dividend safety
61/100

Humana Inc. (HUM) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Humana Inc. (HUM) trades at a EV/EBITDA of 11.5×. Over the past ten years it has ranged from 3.6× (March 2026) to 15.9× (December 2021); the current reading is higher than 89% of that period. That is in line with the Healthcare Plans industry median of 11.5× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 6.8× 9.29%
FY2024 6.2× (37.09%)
FY2023 9.9× (17.49%)
FY2022 11.9× (17.10%)
FY2021 14.4× 84.73%
FY2020 7.8× (26.17%)
FY2019 10.6× 15.97%
FY2018 9.1× 56.14%
FY2017 5.8× (41.89%)
FY2016 10.0× 33.94%

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 10.9× 175.04%
Mar 2026 4.0× (41.38%)
Dec 2025 6.8× 16.33%
Sep 2025 5.8× 17.03%
42 more quarters

Against its own ten years

Low 3.6× High 15.9×
Ten-year median 7.6×
Current reading's percentile 89

EV/EBITDA against peers

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on HUM